Condition: Breast Cancer Triple Negative · Breast Cancer Stage II · Breast Cancer Stage III · Sponsor: Emory University
This research study is a prospective, single arm, pilot study, designed to evaluate the correlation between the immune and clinical responses of subjects with untreated Stage II-III triple negative breast cancer (TNBC) undergoing standard of care neoadjuvant chemo- immunotherapy.
This description comes directly from the study's public registry record.
Ruth Sacks, MD · 404-778-1900 · rlsacks@emory.edu
Always discuss trial participation with your own doctor first.
| Emory University/Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05877859